ResearchIn-Press PreviewNeuroscience Open Access | 10.1172/jci.insight.135391
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Sano, F. in: JCI | PubMed | Google Scholar
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Shigetomi, E. in: JCI | PubMed | Google Scholar |
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Shinozaki, Y. in: JCI | PubMed | Google Scholar |
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Tsuzukiyama, H. in: JCI | PubMed | Google Scholar
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Saito, K. in: JCI | PubMed | Google Scholar
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Mikoshiba, K. in: JCI | PubMed | Google Scholar
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Horiuchi, H. in: JCI | PubMed | Google Scholar
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Cheung, D. in: JCI | PubMed | Google Scholar |
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Nabekura, J. in: JCI | PubMed | Google Scholar
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Sugita, K. in: JCI | PubMed | Google Scholar
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Aihara, M. in: JCI | PubMed | Google Scholar
1Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
3Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan
4Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
Find articles by Koizumi, S. in: JCI | PubMed | Google Scholar |
Published April 8, 2021 - More info
Extensive activation of glial cells during a latent period has been well documented in various animal models of epilepsy. However, it remains unclear whether activated glial cells contribute to epileptogenesis; i.e., the chronically persistent process leading to epilepsy. Particularly, it is not clear whether inter-glial communication between different types of glial cells contributes to epileptogenesis, as past literature mainly focused on one type of glial cell. Here, we show that temporally distinct activation profiles of microglia and astrocytes collaboratively contribute to epileptogenesis in a drug-induced status epilepticus model. We found that reactive microglia appeared first, followed by reactive astrocytes and increased susceptibility to seizures. Reactive astrocytes exhibited larger Ca2+ signals mediated by IP3R2, whereas deletion of this type of Ca2+ signaling reduced seizure susceptibility after status epilepticus. Immediate, but not late, pharmacological inhibition of microglial activation prevented subsequent reactive astrocytes, aberrant astrocyte Ca2+ signaling, and the enhanced seizure susceptibility. These findings indicate that the sequential activation of glial cells constitutes a cause of epileptogenesis after status epilepticus. Thus, our findings suggest that the therapeutic target to prevent epilepsy after status epilepticus should be shifted from microglia (early phase) to astrocytes (late phase).